查看文章

Background: The relative benefits of single vs. dual antiplatelet therapy for the prevention of cerebro-vascular complications after transcatheter bioprosthetic aortic valve replacement (TAVR) remains controversial.

Purpose: Our objective was to compare efficacy and safety of single vs. dual antiplatelet therapy used for prevention of cerebrovascular accidents (CVA) in patients undergoing TAVR.

Methods: We conducted a comprehensive search of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, conference proceedings, and relevant Web sites from inception of TAVR both in Europe and US through January 2018. The primary endpoint was incidence of combined ischemic and hemorrhagic CVA. Secondary endpoints included major bleeding, all-cause mortality, myocardial infarction (MI), and major adverse cardiac events (MACE). Odds ratios (OR) and 95% confidence intervals (CI) were computed …